Patent ID: 6756400
Filing Date: 2004-06-29
Classification: A61P,C07C,C07D

Abstract:
A compound of formula II: wherein: Q is â€”CR5R6â€”wherein Q is attached to each phenyl ring in a para position relative to the oxygen atom attached to each phenyl ring; each R1 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, halo, or Ra; R2 is a covalent bond each R3 is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, oxo, or heterocyclyl; and each R4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, or Rb; or R3 and R4 are joined to form a C1-4 alkylene group, wherein the alkylene group is optionally substituted with 1 to 4 substituents independently selected from Rb; each R5 and R6 is independently hydrogen, or C1-10alkyl; wherein for R1, R3, R4, R5, and R6, each alkyl, alkenyl, and alkynyl is optionally substituted with Rx, or with 1, 2, 3, or 4 substituents independently selected from Rb; for R1-R6, each aryl and heteroaryl is optionally substituted with 1 to 4 substituents independently selected from Rc, and for R1-R6, each cycloalkyl and heterocyclyl is optionally substituted with 1 to 4 substituents independently selected from Rb and Rc; each Ra is independently â€”ORd, â€”NO2, halo, â€”S(O)mRd, â€”SRd, â€”S(O)2ORd, â€”S(O)NRdRe â€”NRdRe, â€”O(CRfRg)nNRdRe, â€”C(O)Rd, CO2Rd, â€”CO2(CRfRg)nCONRdRe, OC(O)Rd, â€”CN, â€”C(O)NRdRc, â€”NRdC(O)Rc, â€”OC(O)NRdRc, â€”NRdC(O)ORc, â€”NRdC(O)NRdRe, â€”CRd(&boxH;Nâ€”ORc), â€”CF3, or â€”OCF3; each Rb is independently Ra, oxo or &boxH;Nâ€”ORc; each Rc is independently Ra, alkyl, alkenyl, or alkynyl; wherein each alkyl, alkenyl and alkynyl is optionally substituted with 1 to 4 substituents independently selected from Rb; each Rd and Re is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; wherein each alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with 1 to 4 substituents independently selected from Rh; or Rd and Re together with the atoms to which they are attached form a heterocyclic ring having from 5 to 7 ring atoms, wherein the heterocyclic ring optionally contains 1 or 2 additional heteroatoms independently selected from oxygen, sulfur or nitrogen; each Rf and Rg is independently hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; wherein each alkyl, aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with 1 to 4 substituents independently selected from Rh; or Rf and Rg together with the carbon atom to which they are attached form a ring having from 5 to 7 ring atoms, wherein the ring optionally contains 1 or 2 heteroatoms independently selected from oxygen, sulfur or nitrogen, each Rh is independently halo, C1-6 alkyl, C1-6 alkoxy, aryl, (aryl)-C1-6 alkyl, heteroaryl, (heteroaryl)-C1-6 alkyl, hydroxy, amino, â€”NHC1-6 alkyl, â€”N(C1-6 alkyl)2, â€”OC(O)C1-6 alkyl, â€”C(O)C1-6 alkyl, â€”C(O)OC1-6 alkyl, â€”NHC(O)C1-6 alkyl, â€”C(O)NHC1-6 alkyl, carboxy, nitro, â€”CN, or â€”CF3; each Rx is independently aryl, heteroaryl, cycloalkyl or heterocyclyl; wherein each aryl or heteroaryl is optionally substituted with 1 to 4 substituents selected from the group consisting of Rc, and wherein each cycloalkyl and heterocyclyl is optionally substituted with 1 to 4 substituents selected from Rb; m is 0, 1, or 2; n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; each w is independently 1 or 2; each y is 1; and each z is independently 0, 1, 2, 3, or 4; or a pharmaceutically-acceptable salt thereof.